Edge Therapeutics, which is developing a sustained-release therapy for limiting brain injury after aneurysms, raised $80 million by offering 7.3 million shares at $11, far below the range of $14 to $16. Edge Therapeutics plans to list on the Nasdaq under the symbol EDGE. Edge Therapeutics initially filed confidentially on 3/21/2014. Leerink Partners and Credit Suisse acted as lead managers on the deal.
